February 26, 2011. Helsinki, Finland – MediSapiens, world’s first software company for personalized cancer medicine in oncology clinics and drug development, received approximately $ 1 million (€ 0.75 million) from the Finnish Funding Agency for Technology and Innovation. With the funding, MediSapiens will continue developing its genomics software for biopharmaceutical research and oncology clinics.
MediSapiens hosts world’s largest unified gene expression database of human tissues and diseases. This enables scientists to understand the role of human genes in health and disease – to be applied in helping oncologists in choosing optimal treatments and biopharmaceutical companies in developing next generation personalized medicines.
“Our software has been received well by both new drug researchers and oncologists. The MediSapiens software is easy-to-use, rich in analysis functionality and gives personalized insight into each patient’s cancer on a molecular level”, says Tommi Pisto, CEO and Software Co-founder of MediSapiens.
“Benefits of using high-quantity gene expression data, especially when linked to other available information, can be significant. While ready for the next generation sequencing data to accumulate, our software builds on the most current science in molecular medicine”, comments Sami Kilpinen, Science and Bioinformatics Co-founder of MediSapiens.
MediSapiens, the world’s first software company for personalized cancer medicine in oncology clinics and new drug development, hosts world’s largest unified gene expression database. With the data online, oncologists have access to evaluate individual patient’s genetic signature for the optimized treatment strategy, and scientists understand how genes work across all human tissues. Company’s bioinformatics science and peer-reviewed data is based on the research since 2005 by VTT Technical Research Centre of Finland and its collaborators. Visit http://www.medisapiens.com for more information.
Tekes is the most important publicly funded expert organization for financing research, development and innovation in Finland. Tekes promotes a broad-based view on innovation: besides funding technological breakthroughs, Tekes emphasizes the significance of service-related, design, business and social innovations. Research, development and innovation funding is targeted to
projects that create in the long-term the greatest benefits for the economy and society. Visit http://www.tekes.fi/en for more information.